Akums Drugs And Pharmaceuticals Q2 FY27: revenue up 31.9% to ₹1,342 Cr, net profit up 176.7% to ₹113 Cr
Results · Finvezto · 3 Nov 2026 · Akums Drugs And Pharmaceuticals (AKUMS)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 1,342 | - | +31.9% |
| Operating profit | 195 | - | +106.1% |
| Net profit | 113 | - | +176.7% |
| Operating margin | 14.5% | - | +5.2 pp |
| Net margin | 8.4% | - | +4.4 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Consolidated revenue grew 31.9% year-on-year to INR 1,342 crores, while EBITDA surged 106% to INR 195 crores with margins expanding to 14.5%. Earnings call
- CDMO revenue rose 38.6% year-on-year to INR 1,115 crores, driven by sustained double-digit volume growth exceeding 20% across customer segments. Earnings call
- The company integrated two acquired Oriflame plants for personal care and is commissioning an oral solids facility in Baddi with 6 billion units capacity. Earnings call
What to watch
- Management on european cdmo supplies: Our European CDMO project is progressing as per our stated plans with supplies commencing in FY28.
- Management on baddi facility capacity: The plant will have oral solids in Phase 1 with an annual capacity of over 6 billion units, which will fully operationalize by Q1 FY28.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.